Expression of somatostatin receptors, SSTR2A and SSTR 5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies

Human Pathology

Volumn 45, Issue 1, 2014, Pages 71-77

  Chinezu, Laura ^a   Vasiljevic, Alexandre ^b,c   Jouanneau, Emmanuel ^b,c   François, Patrick ^d   Borda, Angela ^a   Trouillas, Jacqueline ^b,c   Raverot, Gerald ^b,c  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d CHU BRETONNEAU   (France)

Author keywords

Immunohistochemistry; Monoclonal antibodies; Pituitary tumors; Somatostatin analogs; Somatostatin receptors

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY UMB 1; MONOCLONAL ANTIBODY UMB 4; PROLACTIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2A; SOMATOSTATIN RECEPTOR 5; THYROTROPIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

IMMUNOHISTOCHEMISTRY; MONOCLONAL ANTIBODIES; PITUITARY TUMORS; SOMATOSTATIN ANALOGS; SOMATOSTATIN RECEPTORS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOHISTOCHEMISTRY; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84890129413     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.08.007     Document Type: Article

References (33)

1. C. Bruns, G. Weckbecker, and F. Raulf Molecular pharmacology of somatostatin-receptor subtypes Ann NY Acad Sci 733 1994 138 146
2. T. Reisine, and G.I. Bell Molecular biology of somatostatin receptors Endocrinol Rev 16 4 1995 427 442
3. Y.C. Patel Molecular pharmacology of somatostatin receptor subtypes J Endocrinol Invest 20 6 1997 348 367
4. Y.C. Patel Somatostatin and its receptor family Front Neuroendocrinol 20 3 1999 157 198
5. A. Colao, R.S. Auriemma, G. Lombardi, and R. Pivonello Resistance to somatostatin analogs in acromegaly Endocr Rev 32 2 2011 247 271
6. M. Takei, M. Suzuki, and H. Kajiya Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide Endocr Pathol 18 4 2007 208 216
7. D. Ferone, W.W. de Herder, and R. Pivonello Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy J Clin Endocrinol Metab 93 4 2008 1412 1417
8. L. Vieira Neto, G.F. Taboada, and M.R. Gadelha Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly Arq Bras Endocrinol Metabol 52 8 2008 1288 1295
9. U. Plockinger, S. Albrecht, and C. Mawrin Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas J Clin Endocrinol Metab 93 4 2008 1203 1210
10. I. Lewis, W. Bauer, and R. Albert A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential J Med Chem 46 12 2003 2334 2344
11. H.A. Schmid, and P. Schoeffter Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors Neuroendocrinology 80 Suppl 1 2004 47 50
12. L.J. Hofland, J. van der Hoek, and R. Feelders Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects J Endocrinol Invest 28 11 Suppl International 2005 36 42
13. P. Ma, Y. Wang, and J. van der Hoek Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly Clin Pharmacol Ther 78 1 2005 69 80
14. H.A. Schmid Pasireotide (SOM230): development, mechanism of action and potential applications Mol Cell Endocrinol 286 1-2 2008 69 74
15. H.A. Schmid Preclinical evidences suggest new treatment options for endocrine disorders: pasireotide (SOM230) and everolimus (RAD001) Ann Endocrinol (Paris) 69 2 2008 162 163
16. C. Ramírez, S. Cheng, and G. Vargas Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study J Clin Endocrinol Metab 97 5 2012 1745 1751
17. M. Pawlikowski, H. Pisarek, J. Kunert-Radek, and A. Radek Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas Endocr Pathol 14 3 2003 231 238
18. F. Gatto, R.A. Feelders, and R. van der Pas Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly J Clin Endocrinol Metab 98 1 2013 E66 E71
19. T. Fischer, C. Doll, S. Jacobs, A. Kolodziej, R. Stumm, and S. Schulz Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1 J Clin Endocrinol Metab 93 11 2008 4519 4524
20. A. Lupp, A. Hunder, A. Petrich, F. Nagel, C. Doll, and S. Schulz Reassessment of sst5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4 Neuroendocrinology 94 3 2011 255 264
21. R.V. Lloyd, K. Kovacs, and W.F. Young Jr. Pituitary tumors: introduction R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng, Tumors of the pituitary, chapter 1. Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours 2004 IARC Press Lyon 10 13
22. J. Trouillas, P. Roy, and N. Sturm A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up Acta Neuropathol 126 1 2013 123 135
23. A. Obari, T. Sano, and K. Ohyama Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form Endocr Pathol 19 2 2008 82 91
24. S.L. Fougner, O.C. Borota, J.P. Berg, J.K. Hald, J. Ramm-Pettersen, and J. Bollerslev The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma Clin Endocrinol (Oxf) 68 3 2008 458 465
25. L.J. Hofland, and S.W. Lamberts The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 1 2003 28 47
26. E. Thodou, G. Kontogeorgos, D. Theodossiou, and M. Pateraki Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas J Clin Pathol 59 3 2006 274 279
27. L.E. Wildemberg, L. Vieira Neto, and D.F. Costa Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry J Endocrinol Invest 35 6 2012 580 584
28. S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, and J. Bollerslev Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly Clin Endocrinol (Oxf) 76 1 2012 96 102
29. Y. Bakhtiar, H. Hirano, and K. Arita Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae Eur J Endocrinol 163 4 2010 531 539
30. A. Fusco, A. Giampietro, and A. Bianchi Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study Pituitary 15 4 2012 571 578
31. W. Hassaneen, D.P. Cahill, G.N. Fuller, and N.B. Levine Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in Cushing adenoma J Neurooncol 98 1 2010 151 152
32. A. Colao, S. Petersenn, and J. Newell-Price A 12-month phase 3 study of pasireotide in Cushing's disease N Engl J Med 366 10 2012 914 924 10.1056/NEJMoa1105743
33. L.J. Hofland, J. van der Hoek, and P.M. van Koetsveld The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro J Clin Endocrinol Metab 89 4 2004 1577 1585